Clinical trial · Observational
Observational Study to Evaluate Hematopoietic Progenitor Cell Mobilization in Patients With Newly Diagnosed Multiple Myeloma
A Prospective, Multicenter, Observational Study to Evaluate Hematopoietic Progenitor Cell Mobilization in Patients With Newly Diagnosed Multiple Myeloma
NCT03200626CI-TRIAL-00065059completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Prospective, multicenter, observational registry of myeloma patients undergoing hematopoietic progenitor cell mobilization for upfront autologous transplantation.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bone Marrow Transplant Complications | — | UNRESOLVED | — |
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Autologous hematopoietic cell transplant | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Cytokine alone or JIT plerixafor based mobilization
- interventionNames
- Procedure: Autologous hematopoietic cell transplant
- label
- Routine plerixafor based mobilization
- interventionNames
- Procedure: Autologous hematopoietic cell transplant
- label
- Chemomobilization
- interventionNames
- Procedure: Autologous hematopoietic cell transplant
Primary outcomes (4)
- measure
- Total CD34+ cell yield on the first apheresis
- timeFrame
- 6/1/17-1/1/19
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Myeloma patients ages 18-70 years. * Undergoing upfront autoHCT (≤12 months from start of initial therapy for myeloma). Exclusion Criteria: * Patients with light chain (AL) amyloidosis or myeloma with associated AL amyloidosis. * POEMS syndrome
References
Publications (0)
Data not yet available
No reference posted for this study.